NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00001495
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection
Phase 1
Completed
- Conditions
- HIV Infection
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00001445
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
Phase 1
Completed
- Conditions
- Hemoglobin SC DiseaseSickle Cell Anemia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 50
- Registration Number
- NCT00005783
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors
Phase 1
Completed
- Conditions
- LymphomaNeoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2006-07-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001579
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Study of Scaling Disorders and Other Inherited Skin Diseases
Completed
- Conditions
- Genetic Skin DiseaseKeratosis FollicularisLamellar Ichthyosis
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00001292
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Studies of Patients With Skin Disease, Patients With Neurological Degenerations, and Normal Volunteers
Completed
- Conditions
- HealthyMuscular DystrophyRetinal DegenerationSkin DiseasesVirus Diseases
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00001164
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
The Treatment of Grade I Sarcomas and Benign, Non-Metastasizing Highly Invasive Soft Tissue Tumors
Phase 2
Completed
- Conditions
- SarcomaNeoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 150
- Registration Number
- NCT00001189
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00001382
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas
Phase 1
Completed
- Conditions
- Gastrointestinal NeoplasmsPancreatic Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00001431
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy
Phase 1
Completed
- Conditions
- Brain NeoplasmsNeuroblastoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001565
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath